Cytokinetics is a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of people living with …

Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential …

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for …

Dec 29, 2023 · Pharmaceutical company Cytokinetics announced Wednesday that its drug aficamten produced, "statistically significant and clinically meaningful" results in the phase …

Cytokinetics scientists and collaborators are committed to high scientific and ethical publications standards and are dedicated to providing our science to the medical and scientific community …

Dec 27, 2023 · Cytokinetics said on Wednesday that its experimental heart disease drug met the main goal of a keenly awaited late-stage study, putting it on track to compete with a rival …

Dec 27, 2023 · About Cytokinetics . Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in …

Apr 10, 2024 · Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy . Two Additional Analyses from …

Find the latest Cytokinetics, Incorporated (CYTK) stock quote, history, news and other vital information to help you with your stock trading and investing.

Jan 13, 2025 · Cytokinetics, Incorporated PDUFA Target Action Date for Aficamten Set for September 26, 2025; Commercial Launch Preparations Underway for First Potential Approval